Leitlinie zur (allergen-)spezifischen Immuntherapie bei IgE-vermittelten allergischen Erkrankungen
详细信息    查看全文
  • 作者：Prof. Dr. Oliver Pfaar (1) (2)
    Claus Bachert (3)
    Albrecht Bufe (4)
    Roland Buhl (5)
    Christof Ebner (6)
    Peter Eng (7)
    Frank Friedrichs (8)
    Thomas Fuchs (9)
    Eckard Hamelmann (10)
    Doris Hartwig-Bade (11)
    Thomas Hering (12)
    Isidor Huttegger (13)
    Isidor Huttegger (13)
    Kirsten Jung (14)
    Ludger Klimek (1)
    Matthias Volkmar Kopp (15)
    Hans Merk (16)
    Uta Rabe (17)
    Joachim Saloga (18)
    Peter Schmid-Grendelmeier (19)
    Antje Schuster (20)
    Nicolaus Schwerk (21)
    Helmut Sitter (22)
    Ulrich Umpfenbach (23)
    Bettina Wedi (24)
    Stefan W枚hrl (25)
    Margitta Worm (26)
    J枚rg Kleine-Tebbe (27)
    Susanne Kaul (28)
    Anja Schwalfenberg (29)

    1. Zentrum f眉r Rhinologie und Allergologie     ; HNO-Universit盲tsklinik Mannheim ; An den Quellen 10 ; 65189 ; Wiesbaden ; Deutschland
    2. Universit盲ts-HNO-Klinik Mannheim     ; Mannheim ; Deutschland
    3. HNO-Universit盲tsklinik     ; Gent ; Belgien
    4. Abteilung f眉r Experimentelle Pneumologie     ; Ruhr-Universit盲t Bochum ; Bochum ; Deutschland
    5. III. Medizinische Klinik und Poliklinik     ; Schwerpunkt Pneumologie ; Johannes-Gutenberg-Universit盲t ; Mainz ; Deutschland
    6. Ambulatorium f眉r Allergie und klinische Immunologie     ; Wien ; 脰sterreich
    7. Klinik f眉r Kinder und Jugendliche     ; Aarau und Kinderspital Luzern ; Aarau ; Schweiz
    8. Laurensberg     ; Deutschland
    9. Klinik f眉r Dermatologie     ; Venerologie und Allergologie ; Universit盲tsmedizin G枚ttingen ; Georg-August-Universit盲t ; G枚ttingen ; Deutschland
    10. Klinik f眉r Kinder- und Jugendmedizin     ; Kinderzentrum Bethel ; Evangelisches Krankenhaus Bielefeld ; Bielefeld ; Deutschland
    11. Hals-Nasen-Ohrenarzt-Praxis     ; L眉beck ; Deutschland
    12. Lungenarztpraxis Tegel     ; Berlin ; Deutschland
    13. Universit盲tsklinik f眉 r Kinder- und Jugendheilkunde     ; Paracelsus Medizinische Privatuniversit盲t ; Salzburger Landeskliniken ; Salzburg ; 脰sterreich
    14. Erfurt     ; Deutschland
    15. Klinik f眉r Kinder- und Jugendmedizin     ; UKSH ; Universit盲t zu L眉beck ; Airway Research Center North (ARCN) ; Mitglied des Deutschen Zentrums f眉r Lungenforschung (DZL) ; L眉beck ; Deutschland
    16. Klinik f眉r Dermatologie und Allergologie 鈥?Hautklinik     ; Rheinisch-Westf盲lische Technische Hochschule ; Aachen ; Deutschland
    17. Abteilung Pneumologie     ; Klinik III ; Johanniterkrankenhaus im Fl盲mig ; Treuenbrietzen ; Deutschland
    18. Hautklinik und Poliklinik     ; Universit盲tsmedizin ; Johannes Gutenberg-Universit盲t Mainz ; Mainz ; Deutschland
    19. Allergiestation     ; Dermatologische Universit盲tsklinik ; Z眉rich ; Schweiz
    20. Zentrum f眉r Kinder- und Jugendmedizin     ; Universit盲tsklinikum D眉sseldorf ; D眉sseldorf ; Deutschland
    21. Zentrum f眉r Kinderheilkunde und Jugendmedizin     ; Klinik f眉r P盲diatrische Pneumologie ; Allergologie und Neonatologie ; Medizinische Hochschule Hannover ; Hannover ; Deutschland
    22. Institut f眉r theoretische Chirurgie     ; Universit盲t Marburg ; Marburg ; Deutschland
    23. Viersen     ; Deutschland
    24. Klinik f眉r Dermatologie     ; Allergologie und Venerologie ; Medizinische Hochschule Hannover ; Hannover ; Deutschland
    25. Floridsdorfer Allergiezentrum (FAZ)     ; Wien ; 脰sterreich
    26. Allergie-Centrum-Charit茅     ; Klinik f眉r Dermatologie ; Venerologie und Allergologie ; Charit茅 鈥?Universit盲tsmedizin Berlin ; Berlin ; Deutschland
    27. Allergie- und Asthma-Zentrum Westend     ; Berlin ; Deutschland
    28. Abteilung Allergologie     ; Paul-Ehrlich-Institut ; Langen ; Deutschland
    29. Deutscher Allergie- und Asthmabund     ; M枚nchengladbach ; Deutschland
  • 关键词：(Allergen ; )spezifische Immuntherapie ; Hyposensibilisierung ; Leitlinie ; Allergen ; Allergenextrakt ; allergische Erkrankung ; allergische Rhinitis ; allergisches Asthma
  • 刊名：Allergo Journal
  • 出版年：2014
  • 出版时间：December 2014
  • 年：2014
  • 卷：23
  • 期：8
  • 页码：28-67
  • 全文大小：1,341 KB
  • 参考文献：1. Kleine-Tebbe, J., Bufe, A., Ebner, C. (2009) Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Leitlinie der Deutschen Gesellschaft f眉r Allergologie und klinische Immunologie (DGAKI), des 脛rzteverbandes Deutscher Allergologen (脛DA), der Gesellschaft f眉r P盲diatrische Allergologie und Umweltmedizin (GPA), der 脰sterreichischen Gesellschaft f眉r Allergologie und Immunologie (脰GAI) und der Schweizerischen Gesellschaft f眉r Allergologie und Immunologie (SGAi). Allergo J 18: pp. 509-37
    2. Bagnasco, M., Altrinetti, V., Pesce, G. (2005) Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol 138: pp. 197-202
    3. Martinez-G贸mez, J.M., Johansen, P., Erdmann, I., Senti, G., Crameri, R., K眉ndig, T.M. (2009) Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol 150: pp. 59-65
    4. Allam, J.P., W眉rtzen, P.A., Reinartz, M. (2010) Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J Allergy Clin Immunol 126: pp. 638-45.e1
    5. Akdis, M., Akdis, C.A. (2007) Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 119: pp. 780-91
    6. Nouri-Aria, K.T., Wachholz, P.A., Francis, J.N. (2004) Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 172: pp. 3252-9
    7. Takhar, P., Smurthwaite, L., Coker, H.A. (2005) Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol 174: pp. 5024-32
    8. Reisinger, J., Horak, F., Pauli, G. (2005) Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 116: pp. 347-54
    9. Akdis, M., Verhagen, J., Taylor, A. (2004) Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 199: pp. 1567-75
    10. Li, J.T., Lockey, R.F., Bernstein, I., Portnoy, J.M., Nicklas, R.A. (2003) Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 90: pp. 1-40
    11. European Medicines Agency; Committee for medicinal products for human use (CHMP). Guideline on allergen products: production and quality issues. EMEA/CHMP/BWP/304831/ 2007. London, 20 November, 2008
    12. Ree, R., Chapman, M.D., Ferreira, F. (2008) The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 63: pp. 310-26
    13. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, eds. Monograph: Allergen Products 鈥?Producta Allergenica 07/2014:1063. as implemented of 01.07.2014. Strasbourg: Council of Europe; 2014:p. 3945鈥?7
    14. Grammer, L.C., Shaughnessy, M.A., Patterson, R. (1985) Modified forms of allergen immunotherapy. J Allergy Clin Immunol 76: pp. 397-401
    15. Pfaar, O., Kleine-Tebbe, J., H枚rmann, K., Klimek, L. (2011) Allergen-specific immunotherapy: which outcome measures are useful in monitoring clinical trials?. Immunol Allergy Clin North Am 31: pp. 289-309
    16. Calderon, M.A., Eichel, A., Makatsori, M., Pfaar, O. (2012) Comparability of subcutaneous and sublingual immunotherapy outcomes in allergic rhinitis clinical trials. Curr Opin Allergy Clin Immunol 12: pp. 249-56
    17. Pfaar, O., Demoly, P., Gerth van Wijk, R. (2014) Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy 69: pp. 854-67
    18. Grouin, J.M., Vicaut, E., Jean-Alphonse, S. (2011) The average adjusted symptom score, a new primary efficacy end-point for specific allergen immunotherapy trials. Clin Exp Allergy 41: pp. 1282-8
    19. Didier, A., Melac, M., Montagut, A., Lheritier-Barrand, M., Tabar, A., Worm, M. (2009) Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy 64: pp. 166-71
    20. Clark, J., Schall, R. (2007) Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials. Allergy 62: pp. 1023-8
    21. European Medicines Agency; Commitee for medicinal products for human use (CHMP), eds. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006. London, 20. November 2008
    22. Bousquet, J., Sch眉nemann, H.J., Bousquet, P.J. (2011) How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2)LEN statement. Allergy 66: pp. 765-74
    23. Bousquet, P.J., Brozek, J., Bachert, C. (2009) The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. Allergy 64: pp. 1737-45
    24. Brehler, R., Klimek, L., Kopp, M.V., Christian Virchow, J. (2013) Specific immunotherapy-indications and mode of action. Dtsch Arztebl Int 110: pp. 148-58
    25. Verordnung 眉ber die Ausdehnung der Vorschriften 眉ber die Zulassung der Arzneimittel auf Therapieallergene, die f眉r einzelne Personen auf Grund einer Rezeptur hergestellt werden, sowie 眉ber Verfahrensregelungen der staatlichen Chargenpr眉fung (Therapieallergene-Verordnung). Bundesgesetzbl 2008;51:2177鈥?
    26. Englert, S., May, S., Kaul, S., Vieths, S. (2012) Die Therapieallergene-Verordnung. Hintergrund und Auswirkungen. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 55: pp. 351-57
    27. Kaul, S., Jappe, U., Vieths, S., May, S. (2008) 脺berwachung von Allergenextrakten zur spezifischen Immuntherapie: rechtliche Grundlagen und Verfahren. Allergo J 17: pp. 385-93
    28. May, S., Haustein, D. (2001) Die individuelle Rezeptur in der spezifischen Immuntherapie. Notwendigkeit und Fehlerquellen. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 44: pp. 719-23
    29. Incorvaia, C., Agostinis, F., Amoroso, S. (2007) Pharmacoeconomics of subcutaneous allergen immunotherapy. Eur Ann Allergy Clin Immunol 39: pp. 17-20
    30. Incorvaia, C., Mauro, M., Ridolo, E. (2008) Patient鈥檚 compliance with allergen immunotherapy. Patient Prefer Adherence 2: pp. 247-51
    31. Bocking, C., Renz, H., Pfefferle, P.I. (2012) Pr盲valenz und sozio枚konomische Bedeutung von Allergien in Deutschland. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 55: pp. 303-7
    32. Lamb, C.E., Ratner, P.H., Johnson, C.E. (2006) Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin 22: pp. 1203-10
    33. Shaaban, R., Zureik, M., Soussan, D. (2008) Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 372: pp. 1049-57
    34. Jacobsen, L., Niggemann, B., Dreborg, S. (2007) Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62: pp. 943-8
    35. Hagen A, Gorenoi V, Schonermark MP. Specific immunotherapy (SIT) in the treatment of allergic rhinitis. GMS Health Technol Assess 2010;6:Doc01 doi: 10.3205/hta000079
    36. Ronaldson, S., Taylor, M., Bech, P.G., Shenton, R., Bufe, A. (2014) Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax(庐)) in children. Clinicoecon Outcomes Res 6: pp. 187-96
    37. Br眉ggenj眉rgen, B., Reinhold, T., Brehler, R. (2008) Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann Allergy Asthma Immunol 101: pp. 316-24
    38. Westerhout, K.Y., Verheggen, B.G., Schreder, C.H., Augustin, M. (2012) Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. J Med Econ 15: pp. 906-17
    39. Sch盲dlich, P.K., Brecht, J.G. (2000) Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 17: pp. 37-52
    40. Bachert, C. (2007) Comparison of solutions for sublingual immunotherapy. Int Arch Allergy Immunol 142: pp. 89-90
    41. Calderon, M.A., Casale, T.B., Togias, A., Bousquet, J., Durham, S.R., Demoly, P. (2011) Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 127: pp. 30-8
    42. Compalati, E., Penagos, M., Tarantini, F., Passalacqua, G., Canonica, G.W. (2009) Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol 102: pp. :22-8
    43. Calderon, M., M枚sges, R., Hellmich, M., Demoly, P. (2010) Towards evidence-based medicine in specific grass pollen immunotherapy. Allergy 65: pp. 420-34
    44. Dretzke, J., Meadows, A., Novielli, N., Huissoon, A., Fry-Smith, A., Meads, C. (2013) Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol 131: pp. 1361-6
    45. Calderon, M.A., Casale, T.B., Nelson, H.S., Demoly, P. (2013) An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol 132: pp. 1322-36
    46. Canonica, G.W., Baena-Cagnani, C.E., Bousquet, J. (2007) Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 62: pp. 317-24
    47. Carr, W., Bernstein, J., Lieberman, P. (2012) A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 129: pp. 1282-9.e10
    48. Calderon, M.A., Alves, B., Jacobson, M., Hurwitz, B., Sheikh, A., Durham, S. (2007) Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 1: pp. CD001936
    49. Matricardi, P.M., Kuna, P., Panetta, V., Wahn, U., Narkus, A. (2011) Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses. J Allergy Clin Immunol 128: pp. 791-9.e6
    50. Kuna, P., Kaczmarek, J., Kupczyk, M. (2011) Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. J Allergy Clin Immunol 127: pp. 502-8
    51. Bergmann, K.C. (2003) Spezifische Immuntherapie bei allergischem Asthma bronchiale. Pneumologie 57: pp. 84-90
    52. Bousquet, J., Lockey, R.F., Malling, H.J. (1998) Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO Position paper. Allergy 53: pp. 1-42
    53. Buhl, R., Berdel, D., Cri茅e, C.P. (2006) Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma. Pneumologie 60: pp. 139-83
    54. Gillissen, A., Bergmann, K.C., Kleine-Tebbe, J. (2003) Die spezifische Immuntherapie bei allergischem Asthma. Dtsch Med Wochenschr 128: pp. 204-9
    55. Global Initiative for Asthma (GINA), ed. Global strategy for asthma management and prevention (updated 2005). www.ginasthma.org
    56. Global Initiative for Asthma (GINA), ed. Global strategy for asthma management and prevention (updated 2007). www.ginasthma.org
    57. Walker, S.M., Durham, S.R., Till, S.J. (2011) Immunotherapy for allergic rhinitis. Clin Exp Allergy 41: pp. 1177-200
    58. Bousquet, J. (1999) Specific immunotherapy in asthma. Allergy 54: pp. 37-8
    59. Abramson, M.J., Puy, R.M., Weiner, J.M. (2010) Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 8: pp. CD001186
    60. Amin, H.S., Liss, G.M., Bernstein, D.I. (2006) Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 117: pp. 169-75
    61. Zielen, S., Kardos, P., Madonini, E. (2010) Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol 126: pp. 942-9
    62. Frew, A.J., Powell, R.J., Corrigan, C.J., Durham, S.R. (2006) Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117: pp. 319-25
    63. Corrigan, C.J., Kettner, J. ^. C., Cromwell, O., Narkus, A. (2005) Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 60: pp. 801-7
    64. Pfaar, O., Urry, Z., Robinson, D.S. (2012) A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy 67: pp. 272-9
    65. Dubuske, L., Frew, A., Horak, F. (2011) Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 32: pp. 239-47
    66. Brewczynski, P., Kroon, A. (1999) Wirksamkeit und Vertr盲glichkeit einer Immuntherapie mit modifizierten Gr盲serpollenallergenen. Allergologie 22: pp. 411-20
    67. Roberts, G., Hurley, C., Turcanu, V., Lack, G. (2006) Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 117: pp. 263-8
    68. Arvidsson, M.B., L枚whagen, O., Rak, S. (2002) Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 109: pp. 777-83
    69. Balda, B.R., Wolf, H., Baumgarten, C. (1998) Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens. Allergy 53: pp. 740-8
    70. B酶dtger, U., Poulsen, L.K., Jacobi, H.H., Malling, H.J. (2002) The safety and efficacy of subcutaneous birch pollen immunotherapy 鈥?a one-year, randomised, double-blind, placebo-controlled study. Allergy 57: pp. 297-305
    71. Neerven, R.J., Arvidsson, M., Ipsen, H., Sparholt, S.H., Rak, S., W眉rtzen, P.A. (2004) A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy 34: pp. 420-8
    72. Hoiby, A.S., Strand, V., Robinson, D.S., Sager, A., Rak, S. (2010) Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 40: pp. 1062-70
    73. Pfaar, O., Robinson, D.S., Sager, A., Emuzyte, R. (2010) Immunotherapy with depigmented-polymerized mixed tree pollen extract: a clinical trial and responder analysis. Allergy 65: pp. 1614-21
    74. Drachenberg, K.J., Heinzkill, M., Urban, E. (2002) Kurzzeit-Immuntherapie mit Baumpollen-Allergoiden und dem Adjuvanz Monophosphoryl Lipid A. Ergebnisse einer randomisierten, doppelblinden, plazebokontrollierten Multicenterstudie. Allergologie 25: pp. 466-74
    75. Ameal, A., Vega-Chicote, J.M., Fern谩ndez, S. (2005) Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy 60: pp. 1178-83
    76. Pichler, C.E., Marquardsen, A., Sparholt, S. (1997) Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 52: pp. 274-83
    77. Riechelmann, H., Schmutzhard, J., Werf, J.F., Distler, A., Kleinjans, H.A. (2010) Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis. Am J Rhinol Allergy 24: pp. e104-9
    78. Varney, V.A., Tabbah, K., Mavroleon, G., Frew, A.J. (2003) Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin Exp Allergy 33: pp. 1076-82
    79. Blainey, A.D., Phillips, M.J., Ollier, S., Davies, R.J. (1984) Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus in adults with perennial rhinitis. A controlled clinical trial. Allergy 39: pp. 521-8
    80. Yukselen, A., Kendirli, S.G., Yilmaz, M., Altintas, D.U., Karakoc, G.B. (2012) Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol 157: pp. 288-98
    81. Olsen, O.T., Larsen, K.R., Jacobsan, L., Svendsen, U.G. (1997) A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 52: pp. 853-9
    82. Wang, H., Lin, X., Hao, C. (2006) A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy 61: pp. 191-7
    83. Garcia-Robaina, J.C., Sanchez, I., Torre, F., Fernandez-Caldas, E., Casanovas, M. (2006) Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 118: pp. 1026-32
    84. Blumberga, G., Groes, L., Haugaard, L., Dahl, R. (2006) Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 61: pp. 843-8
    85. Bucur, J., Dreborg, S., Einarsson, R. (1989) Immunotherapy with dog and cat allergen preparations in dog-sensitive and cat-sensitive asthmatics. Ann Allergy 62: pp. 355-61
    86. Hedlin, G., Graff-Lonnevig, V., Heilborn, H. (1991) Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 87: pp. 955-64
    87. Hedlin, G., Heilborn, H., Lilja, G. (1995) Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 96: pp. 879-85
    88. Nanda, A., O鈥機onnor, M., Anand, M. (2004) Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 114: pp. 1339-44
    89. Sundin, B., Lilja, G., Graff-Lonnevig, V. (1986) Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 77: pp. 478-87
    90. Dreborg, S., Agrell, B., Foucard, T., Kjellman, N.I., Koivikko, A., Nilsson, S. (1986) A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy 41: pp. 131-40
    91. Horst, M., Hejjaoui, A., Horst, V., Michel, F.B., Bousquet, J. (1990) Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 85: pp. 460-72
    92. Malling, H.J., Dreborg, S., Weeke, B. (1986) Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy 41: pp. 507-19
    93. Mari, A., Ballmer-Weber, B.K., Vieths, S. (2005) The oral allergy syndrome: improved diagnostic and treatment methods. Curr Opin Allergy Clin Immunol 5: pp. 267-73
    94. Mauro, M., Russello, M., Incorvaia, C. (2011) Birch-apple syndrome treated with birch pollen immunotherapy. Int Arch Allergy Immunol 156: pp. 416-22
    95. Bussmann, C., B枚ckenhoff, A., Henke, H., Werfel, T., Novak, N. (2006) Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis?. J Allergy Clin Immunol 118: pp. 1292-8
    96. Novak, N. (2007) Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol 7: pp. 542-46
    97. Werfel, T., Breuer, K., Rueff, F. (2006) Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 61: pp. 202-5
    98. Novak, N., Bieber, T., Hoffmann, M. (2012) Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol 130: pp. 925-31
    99. Bae, J.M., Choi, Y.Y., Park, C.O., Chung, K.Y., Lee, K.H. (2013) Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 132: pp. 110-7
    100. Dahl, R., Stender, A., Rak, S. (2006) Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 61: pp. 185-90
    101. Dahl, R., Kapp, A., Colombo, G. (2006) Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 118: pp. 434-40
    102. Didier, A., Malling, H.J., Worm, M. (2007) Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 120: pp. 1338-45
    103. Worm, M. (2006) Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis. Allerg Immunol (Paris) 38: pp. 355-60
    104. Durham, S.R., Yang, W.H., Pedersen, M.R., Johansen, N., Rak, S. (2006) Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117: pp. 802-9
    105. Worm, M., Rak, S., Blay, F. (2014) Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study. Clin Transl Allergy 4: pp. 7
    106. Bergmann, K.C., Demoly, P., Worm, M. (2014) Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol 133: pp. 1608-14
    107. Bufe, A., Eberle, P., Franke-Beckmann, E. (2009) Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 123: pp. 167-73
    108. Wahn, U., Tabar, A., Kuna, P. (2009) Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 123: pp. 160-6
    109. Wahn, U., Klimek, L., Ploszczuk, A. (2012) High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. J Allergy Clin Immunol 130: pp. 886-93
    110. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010;(12):CD002893
    111. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003;(2):CD002893
    112. Khinchi, M.S., Poulsen, L.K., Carat, F., Andre, C., Hansen, A.B., Malling, H.J. (2004) Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 59: pp. 45-53
    113. Devillier, P., Dreyfus, J.F., Demoly, P., Calderon, M.A. (2014) A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC medicine 12: pp. 71
    114. Bousquet, J., Scheinmann, P., Guinnepain, M.T. (1999) Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 54: pp. 249-60
    115. Pajno, G.B., Morabito, L., Barberio, G., Parmiani, S. (2000) Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 55: pp. 842-9
    116. Hirsch, T., Sahn, M., Leupold, W. (1997) Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 8: pp. 21-7
    117. Bahceciler, N.N., Isik, U., Barlan, I.B., Basaran, M.M. (2001) Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 32: pp. 49-55
    118. Mosbech, H., Deckelmann, R., Blay, F. (2014) Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 134: pp. 568-75
    119. Nelson, H.S., Nolte, H., Creticos, P., Maloney, J., Wu, J., Bernstein, D.I. (2011) Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 127: pp. 72-80
    120. Canonica, G.W., Cox, L., Pawankar, R. (2014) Sublingual immunotherapy: World Allergy Organization position paper 2013 update. The World Allergy Organization journal 7: pp. 6
    121. Pajno, G.B., Caminiti, L., Crisafulli, G. (2011) Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. Pediatr Allergy Immunol 22: pp. 803-7
    122. Blaiss, M., Maloney, J., Nolte, H., Gawchik, S., Yao, R., Skoner, D.P. (2011) Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 127: pp. 64-71
    123. Didier, A., Malling, H.J., Worm, M. (2013) Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy 43: pp. 568-77
    124. Durham, S.R., Emminger, W., Kapp, A. (2010) Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 125: pp. 131-8
    125. Durham, S.R., Emminger, W., Kapp, A. (2012) SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 129: pp. 717-25
    126. Ott, H., Sieber, J., Brehler, R. (2009) Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 64: pp. 179-86
    127. Pfaar, O., Klimek, L. (2008) Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol 100: pp. 256-63
    128. Drachenberg, K., Pfeiffer, P., Urban, E. (2001) Sublinguale Immuntherapie. Ergebnisse einer randomisierten, doppelblinden, plazebokontrollierten Multicenterstudie mit einem standardisierten Birken- und Gr盲ser-/Roggenpollenextrakt. Allergologie 24: pp. 525-34
    129. Horak, F., St眉bner, P., Berger, U.E., Marks, B., Toth, J. J. S. (1998) Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. J Investig Allergol Clin Immunol 8: pp. 165-71
    130. Tonnel, A.B., Scherpereel, A., Douay, B. (2004) Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 59: pp. 491-7
    131. Passalacqua, G., Albano, M., Fregonese, L. (1998) Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 351: pp. 629-32
    132. Lue, K.H., Lin, Y.H., Sun, H.L., Lu, K.H., Hsieh, J.C., Chou, M.C. (2006) Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 17: pp. 408-15
    133. Niu, C.K., Chen, W.Y., Huang, J.L., Lue, K.H., Wang, J.Y. (2006) Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 100: pp. 1374-83
    134. Passalacqua, G., Pasquali, M., Ariano, R. (2006) Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy 61: pp. 849-54
    135. Guez, S., Vatrinet, C. ^. R., Andre, C. (2000) House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 55: pp. 369-75
    136. M枚ller, C., Dreborg, S., Ferdousi, H.A. (2002) Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 109: pp. 251-6
    137. Niggemann, B., Jacobsen, L., Dreborg, S. (2006) Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 61: pp. 855-9
    138. Eng, P.A., Reinhold, M., Gnehm, H.P. (2002) Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 57: pp. 306-12
    139. Eng, P.A., Borer-Reinhold, M., Heijnen, I.A., Gnehm, H.P. (2006) Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 61: pp. 198-201
    140. Purello-D鈥橝mbrosio, F., Gangemi, S., Merendino, R.A. (2001) Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 31: pp. 1295-302
    141. Pajno, G.B., Barberio, G., Luca, F., Morabito, L., Parmiani, S. (2001) Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 31: pp. 1392-7
    142. Rienzo, V., Marcucci, F., Puccinelli, P. (2003) Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 33: pp. 206-10
    143. Marogna, M., Spadolini, I., Massolo, A., Canonica, G.W., Passalacqua, G. (2010) Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 126: pp. 969-75
    144. Novembre, E., Galli, E., Landi, F. (2004) Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 114: pp. 851-7
    145. Marogna, M., Spadolini, I., Massolo, A., Canonica, G.W., Passalacqua, G. (2004) Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy 59: pp. 1205-10
    146. Valovirta, E., Berstad, A.K., Blic, J. (2011) Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. Clin Ther 33: pp. 1537-46
    147. Schmid-Grendelmeier, P. (2010) Rekombinante Allergene. Routinediagnostik oder Wissenschaft?. Hautarzt 61: pp. 946-53
    148. G枚tzsche, P.C., Johansen, H.K. (2008) House dust mite control measures for asthma: systematic review. Allergy 63: pp. 646-59
    149. Kopp, M.V., Niggemann, B., Forster, J. (2009) House dust mite allergy: complete removal of the provoking allergen is a primary therapeutic approach. Allergy 64: pp. 1402-3
    150. Muche-Borowski, C., Kopp, M., Reese, I. (2009) S3-Leitlinie Allergiepr盲vention 鈥?Update 2009. Allergo J 18: pp. 332-41
    151. Pfaar, O., Biedermann, T., Klimek, L., Sager, A., Robinson, D.S. (2013) Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients. Allergy 68: pp. 1306-13
    152. Nelson, H.S. (2009) Specific immunotherapy with allergen mixes: what is the evidence?. Curr Opin Allergy Clin Immunol 9: pp. 549-53
    153. Bundes盲rztekammer (B脛K), Kassen盲rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), eds. Nationale Versorgungs Leitlinie Asthma 鈥?Langfassung, 2. Aufl. Version 5, 2009, zuletzt ge盲ndert: August 2013. www.leitlinien.de/nvl/asthma/mdb/downloads/nvl/asthma/asthma-2aufl-vers5-lang.pdf
    154. Zuberbier, T., Bachert, C., Bousquet, P.J. (2010) GA(2) LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 65: pp. 1525-30
    155. Demoly, P., Piette, V., Daures, J.P. (2003) Treatment of allergic rhinitis during pregnancy. Drugs 63: pp. 1813-20
    156. Wedi, B., Rueff, F. (2011) Pharmakoprophylaxe und Begleitmedikation bei spezifischer Immuntherapie. Hautarzt 62: pp. 663-70
    157. Fodeman, J., Jariwala, S., Hudes, G., Jerschow, E., Rosenstreich, D. (2010) Subcutaneous allergen immunotherapy in 3 patients with HIV. Ann Allergy Asthma Immunol 105: pp. 320-1
    158. Randhawa, I.S., Junaid, I., Klaustermeyer, W.B. (2007) Allergen immunotherapy in a patient with human immunodeficiency virus: effect on T-cell activation and viral replication. Ann Allergy Asthma Immunol 98: pp. 495-7
    159. W枚hrl, S., Kinaciyan, T., Jalili, A., Stingl, G., Moritz, K.B. (2011) Malignancy and specific allergen immunotherapy: the results of a case series. Int Arch Allergy Immunol 156: pp. 313-9
    160. M眉ller, U.R., Haeberli, G. (2005) Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 115: pp. 606-10
    161. Linneberg, A., Madsen, F., Skaaby, T. (2012) Allergen-specific immunotherapy and risk of autoimmune disease. Curr Opin Allergy Clin Immunol 12: pp. 635-9
    162. Linneberg, A., Jacobsen, R.K., Jespersen, L., Abildstrom, S.Z. (2012) Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J Allergy Clin Immunol 129: pp. 413-9
    163. Arzneimittelkommission der deutschen 脛rzteschaft (Akd脛), ed. Stellungnahme der Akd脛 zur allergenspezifischen Immuntherapie. Dtsch 脛rztebl 2007;104:A3355-7
    164. Zylka-Menhorn, V. (1995) Hyposensibilisierung bald nur noch durch 鈥瀍rfahrene 脛rzte鈥? Dtsch 脛rztebl 92: pp. A-1434
    165. Alvarez-Cuesta, E., Bousquet, J., Canonica, G.W., Durham, S.R., Malling, H.J., Valovirta, E. (2006) Standards for practical allergen-specific immunotherapy. Allergy 61: pp. 1-20
    166. Klimek, L. (2013) Umsetzung der EU-Richtlinie 2010/32/EU fordert verletzungssichere Spritzen: im HNO-Bereich ist hiervon insbesondere auch die subkutane Immuntherapie (SCIT) betroffen. HNO-Mitteilungen 63: pp. 189
    167. Fischer, P.J., Friedrichs, F. (2013) Praktische Durchf眉hrung der Hyposensibilisierung. Monatsschr Kinderheilkd 161: pp. 608-15
    168. Calabria, C.W. (2013) Accelerated immunotherapy schedules. Curr Allergy Asthma Rep 13: pp. 389-98
    169. Calabria, C.W., Cox, L. (2011) Accelerated immunotherapy schedules and premedication. Immunol Allergy Clin North Am 31: pp. 251-63
    170. Pfaar, O., Wolf, H., Klimek, L., Schnitker, J., W眉stenberg, E. (2012) Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial. Clin Ther 34: pp. 2072-81
    171. Canonica, G.W., Bousquet, J., Casale, T. (2009) Sublingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 64: pp. 1-59
    172. Haynes, R. Einleitung. In: Haynes, R.B., Taylor, D.W., Sackett, D.L. eds. (1986) Compliance Handbuch. Oldenbourg, M眉nchen, pp. 11-8
    173. Sondermann, N., Shah-Hosseini, K., Henkel, K., Schwalfenberg, A., M枚sges, R. (2011) Erfolgsfaktoren der Adherence bei Hyposensibilisierung. Allergologie 34: pp. 441-6
    174. Osterberg, L., Blaschke, T. (2005) Adherence to medication. N Engl J Med 353: pp. 487-97
    175. Baiardini, I., Braido, F., Bonini, M., Compalati, E., Canonica, G.W. (2009) Why do doctors and patients not follow guidelines?. Curr Opin Allergy Clin Immunol 9: pp. 228-33
    176. Bousquet, J., Khaltaev, N., Cruz, A.A. (2008) Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63: pp. 8-160
    177. Senna, G., Ridolo, E., Calderon, M., Lombardi, C., Canonica, G.W., Passalacqua, G. (2009) Evidence of adherence to allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 9: pp. 544-8
    178. Claes, C., Mittendorf, T., Graf von der Schulenburg, J.M. (2009) Persistenz und Frequenz von Verordnungen im Bereich der subkutanen allergenspezifischen Immuntherapie (SCIT) bei GKV-Patienten in Deutschland. Med Klin (Munich) 104: pp. 536-42
    179. Aschemann, U., Schulte, P., Hecker, H. (2010) Untersuchung zur Compliance eines anwenderfreundlichen Allergoids. Allergo J 19: pp. 63
    180. Egert-Schmidt, A., Martin, E., M眉ller, U., Schulte, M., Thum-Oltmer, S. (2011) Patienten-Compliance in der Spezifischen Immuntherapie 鈥?Ein Vergleich von SCIT- und SLIT-Pr盲paraten. Allergo J 20: pp. S40
    181. Senna, G., Lombardi, C., Canonica, G.W., Passalacqua, G. (2010) How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers鈥?viewpoint. J Allergy Clin Immunol 126: pp. 668-9
    182. Sieber, J., De Geest, S., Shah-Hosseini, K., M枚sges, R. (2011) Medication persistence with long-term, specific grass pollen immunotherapy measured by prescription renewal rates. Curr Med Res Opin 27: pp. 855-61
    183. Eberle, P., Schreder, H., Shah-Hosseini, K., M枚sges, R. (2013) Medikamenten-Persistenz bei Kindern und Jugendlichen unter einer Langzeithyposensibilisierung mit Gr盲serpollenextrakten. Ergebnisse einer Versorgungsstudie anhand von Verordnungsdaten. Allergologie 36: pp. 9-18
    184. Przybilla, B., Rueff, F., Walker, A. (2011) Diagnose und Therapie der Bienen- und Wespengiftallergie. Allergo J 20: pp. 318-39
    185. Cox, L., Calderon, M., Pfaar, O. (2012) Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations. Immunotherapy 4: pp. 601-16
    186. Malling, H.J. (2000) Minimising the risks of allergen-specific injection immunotherapy. Drug Saf 23: pp. 323-32
    187. Kelso, J.M. (2004) The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol 92: pp. 225-7
    188. Vogelbruch, M., Nuss, B., K枚rner, M., Kapp, A., Kiehl, P., Bohm, W. (2000) Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations. Allergy 55: pp. 883-7
    189. Netterlid, E., Hinds茅n, M., Bj枚rk, J. (2009) There is an association between contact allergy to aluminium and persistent subcutaneous nodules in children undergoing hyposensitization therapy. Contact Dermatitis 60: pp. 41-9
    190. Frost, L., Johansen, P., Pedersen, S., Veien, N., Ostergaard, P.A., Nielsen, M.H. (1985) Persistent subcutaneous nodules in children hyposensitized with aluminium-containing allergen extracts. Allergy 40: pp. 368-72
    191. Lopez, S., Pelaez, A., Navarro, L.A., Montesinos, E., Morales, C., Carda, C. (1994) Aluminium allergy in patients hyposensitized with aluminium-precipitated antigen extracts. Contact Dermatitis 31: pp. 37-40
    192. Ragusa, F.V., Passalacqua, G., Gambardella, R. (1997) Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience. J Investig Allergol Clin Immunol 7: pp. 151-4
    193. Burks, A.W., Calderon, M.A., Casale, T. (2013) Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 131: pp. 1288-96
    194. Epstein, T.G., Liss, G.M., Murphy-Berendts, K., Bernstein, D.I. (2013) AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, year 3: what practices modify the risk of systemic reactions?. Ann Allergy Asthma Immunol 110: pp. 274-8
    195. Bernstein, D.I., Wanner, M., Borish, L., Liss, G.M. (2004) Immunotherapy Committee AAoAA, and Immunology: Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 113: pp. 1129-36
    196. L眉deritz-P眉chel, U., Keller-Stanislawski, B., Haustein, D. (2001) Neubewertung des Risikos von Test- und Therapieallergenen. Eine Analyse der UAW-Meldungen von 1991 bis 2000. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 44: pp. 709-18
    197. Makatsori, M., Calderon, M.A. (2014) Anaphylaxis: still a ghost behind allergen immunotherapy. Curr Opin Allergy Clin Immunol 14: pp. 316-22
    198. Cox, L., Larenas-Linnemann, D., Lockey, R.F., Passalacqua, G. (2010) Speaking the same language: The World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 125: pp. 569-74
    199. Nielsen, L., Johnsen, C.R., Mosbech, H., Poulsen, L.K., Malling, H.J. (1996) Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 97: pp. 1207-13
    200. Reimers, A., Hari, Y., M眉ller, U. (2000) Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 55: pp. 484-8
    201. Cox, L.S., Larenas Linnemann, D., Nolte, H., Weldon, D., Finegold, I., Nelson, H.S. (2006) Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 117: pp. 1021-35
    202. Calderon, M.A., Simons, F.E., Malling, H.J., Lockey, R.F., Moingeon, P., Demoly, P. (2012) Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 67: pp. 302-11
    203. Passalacqua, G., Garelli, V., Sclifo, F., Canonica, G.W. (2013) Sublingual immunotherapy for allergic rhinitis and conjunctivitis. Immunotherapy 5: pp. 257-64
    204. Groot, H., Bijl, A. (2009) Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 64: pp. 963-4
    205. Passalacqua, G., Baena-Cagnani, C.E., Bousquet, J. (2013) Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol 132: pp. 93-8
    206. Swissmedic, ed. Neues Heilmittelgesetz: Meldepflicht der Fachleute f眉r unerw眉nschte Arzneitmittelwirkungen. Schweiz 脛rztezeitung 2002;83:819鈥?2
    207. Ring, J., Beyer, K., Biedermann, T. (2014) Guideline for acute therapy and management of anaphylaxis. S2 Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Association of German Allergologists (AeDA), the Society of Pediatric Allergy and Environmental Medicine (GPA), the German Academy of Allergology and Environmental Medicine (DAAU), the German Professional Association of Pediatricians (BVKJ), the Austrian Society for Allergology and Immunology (脰GAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Anaesthesiology and Intensive Care Medicine (DGAI), the German Society of Pharmacology (DGP), the German Society for Psychosomatic Medicine (DGPM), the German Working Group of Anaphylaxis Training and Education (AGATE) and the patient organization German Allergy and Asthma Association (DAAB). Allergo J Int 23: pp. 96-112
    208. Simons, F.E., Ardusso, L.R., Bilo, M.B. (2012) 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol 12: pp. 389-99
    209. Dhami, S., Panesar, S.S., Rader, T. (2013) The acute and long-term management of anaphylaxis: protocol for a systematic review. Clin Transl Allergy 3: pp. 14
    210. Reeve, L., Baldrick, P., Hewings, S., Skinner, M. (2012) A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPL(R)) for the treatment of grass pollen allergy. J Appl Toxicol 32: pp. 608-16
    211. Pfaar, O., Cazan, D., Klimek, L., Larenas-Linnemann, D., Calderon, M.A. (2012) Adjuvants for immunotherapy. Curr Opin Allergy Clin Immunol 12: pp. 648-57
    212. Jutel, M., Solarewicz-Madejek, K., Smolinska, S. (2012) Recombinant allergens: The present and the future. Hum Vaccin Immunother 8: pp. 1534-43
    213. Patel, D., Couroux, P., Hickey, P. (2013) Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 131: pp. 103-9
    214. Johansen, P., Moos, S., Mohanan, D., K眉ndig, T.M., Senti, G. (2012) New routes for allergen immunotherapy. Hum Vaccin Immunother 8: pp. 1525-33
    215. Senti, G., Prinz Vavricka, B.M., Erdmann, I. (2008) Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 105: pp. 17908-12
    216. Senti, G., Moos, S., Tay, F. (2012) Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 129: pp. 128-35
    217. Senti, G., Crameri, R., Kuster, D. (2012) Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 129: pp. 1290-6
    218. Kopp, M.V. (2011) Role of immunmodulators in allergen-specific immunotherapy. Allergy 66: pp. 792-7
    219. Larenas-Linnemann, D., Wahn, U., Kopp, M. (2014) Use of omalizumab to improve desensitization safety in allergen immunotherapy. J Allergy Clin Immunol 2014: pp. 937
    220. Noon, L. (1911) Prophylactic inoculation against hay fever. Lancet 1: pp. 1572-3
    221. Bousquet, J., Sch眉nemann, H.J., Samolinski, B. (2012) Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol 130: pp. 1049-62
  • 刊物主题：General Practice / Family Medicine;
  • 出版者：Urban & Vogel
  • ISSN：2195-6405
文摘

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址：北京市海淀区学院路29号 邮编：100083

电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700